rhinorsc2reel| Olin Bio: Quadrivalent influenza virus split vaccine (MDCK cells) approved for clinical trials

editor Nature 2024-05-15 5 0

News summary

[Olin Bio: Quadrivalent influenza virus split vaccine (MDCK cells) approved for clinical trials] Securities Times e Company Newsrhinorsc2reel, Orin Biotech (688319) announced on the evening of May 15rhinorsc2reelRecently, the company received approval from the State Food and Drug Administration for the issuance of a tetravalent influenza virus split vaccine (MDCK cells)rhinorsc2reel.rhinorsc2reel..

Newsletter text

[Olin Biological: Quadrivalent influenza virus split vaccine (MDCK cells) has been approved for clinical trials] Securities Times e Company News, Olin Biotech (688319) announced on the evening of May 15 that recently, the company received approval and issuance from the State Food and Drug Administration. The "Drug Clinical Trial Approval Notice" for the Quadrivalent influenza virus split vaccine (MDCK cells) agrees to conduct clinical trials to prevent influenza caused by vaccine-related types of influenza viruses in people aged 6 months and above.

rhinorsc2reel| Olin Bio: Quadrivalent influenza virus split vaccine (MDCK cells) approved for clinical trials